Free Trial
NYSE:HIMS

Hims & Hers Health Q2 2025 Earnings Report

Hims & Hers Health logo
$50.44 -1.59 (-3.05%)
Closing price 03:59 PM Eastern
Extended Trading
$50.49 +0.05 (+0.10%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hims & Hers Health EPS Results

Actual EPS
N/A
Consensus EPS
$0.17
Beat/Miss
N/A
One Year Ago EPS
N/A

Hims & Hers Health Revenue Results

Actual Revenue
N/A
Expected Revenue
$550.06 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hims & Hers Health Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, August 4, 2025
Conference Call Time
5:00PM ET

Conference Call Resources

Hims & Hers Health Earnings Headlines

REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).
See More Hims & Hers Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hims & Hers Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hims & Hers Health and other key companies, straight to your email.

About Hims & Hers Health

Hims & Hers Health (NYSE:HIMS) (NYSE: HIMS) is a telehealth company that operates a direct-to-consumer platform offering prescription and over-the-counter products across a range of wellness categories. Founded in 2017 by Andrew Dudum, the company initially targeted men’s sexual health and hair loss solutions before expanding its offerings in 2020 under the Hims & Hers umbrella. Customers access the platform via its website or mobile app, complete a virtual consultation with a licensed healthcare provider, and receive personalized treatment plans shipped directly to their door.

The company’s portfolio encompasses treatments for hair and skin care, sexual health, mental wellness and general health, as well as nutritional supplements and lifestyle products. Branded formulations include topical minoxidil for hair regrowth, prescription dermatology medications, and FDA-approved therapies for erectile dysfunction and birth control. In addition to medications, Hims & Hers features content and self-care tools designed to educate users on preventive health measures and overall well-being.

Hims & Hers serves primarily the U.S. market, with operations headquartered in San Francisco and satellite offices in New York and Austin. The company went public via a special purpose acquisition company (SPAC) merger in early 2021, positioning itself to accelerate growth through product innovation and geographic expansion. Its technology-driven approach aims to reduce barriers to care by integrating telehealth consultations with in-house pharmacy fulfillment and discreet shipping.

Under the leadership of founder and CEO Andrew Dudum, Hims & Hers has cultivated a multidisciplinary team of medical, regulatory and consumer-brand experts. The company continues to explore new markets and partnerships, leveraging data analytics and digital marketing to refine its product offerings and enhance the patient experience in an evolving virtual care landscape.

View Hims & Hers Health Profile

More Earnings Resources from MarketBeat